Pfizer wants to acquire rival Allergan

The u.s. pharmaceutical giant Pfizer plans to acquire rival Allergan, headquartered in Ireland, a country with taxes lower than the United States, reported a source close to the operation.
Pfizer, based in New York, presented an offer to buy Allergan to between 370 and 380 dollars per share, according to the source, who requested anonymity, information that confirms the news agency Bloomberg News.
The price would establish the value of the manufacturer of the antirrugas treatment Botox at 150 billion dollars. The action of Allergan closed Wednesday's session on Wall Street at $ 310.8.
A 150-billion transaction would make of this operation the biggest merger of the year, ahead of the purchase of that involves beer companies SABMiller and InBev (112 billion dollars).